close

Sun Pharma receives China NMPA's nod for treatment of plaque psoriasis

Ilumetri is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

Sun Pharma

Sun Pharma

BS Web Team New Delhi

Listen to This Article

Sun Pharmaceutical Industries, on Tuesday, announced that its new drug application (NDA) of tildrakizumab injection used for treatment of adults with moderate-to-severe plaque psoriasis approved by the Chinese health authority.

In a regulatory filing, the company said, “The product under the brand name Ilumetri has been approved by China's National Medical Products Administration (NMPA).”

Ilumetri is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

In June 2019, Sun Pharma out-licensed tildrakizumab to a subsidiary of China Medical System Holdings Limited (CMS), for development, regulatory filings and commercialisation of the product in Greater China.

Tildrakizumab injection has also been approved for marketing in the US, EU, Japan, UK, Switzerland, Canada, Australia, Hong Kong and other countries/regions under the brands of Ilumya and Ilumetri in different geographies, the company said in a BSE filing.

Ilumetri is a humanised, anti-IL-23p19 monoclonal antibody designed to selectively block the cytokine IL-23. With this precise targeting, ILUMETRI has the potential to help control the pathogenic cells responsible for the inflammatory process of psoriasis with limited impact on the rest of the immune system.

Also Read

Sun Pharma Q4: Consolidated net profit at Rs 1,984 crore, revenue up 15%

Sun Pharma Q3 net profit up 5.2% as sales grow in India, US markets

India business to boost pharma, after US sales prove to be a mixed bag

Sun Pharmaceuticals' Halol plant gets 'import alert' from USFDA

Mankind Pharma IPO to open next week: Check price band, GMP, other details

Tata Steel Mining partners with METRON to reduce carbon footprint

Lakme Lever revenue rises 19.8% in FY23, HUL's exports at Rs 1,268 cr

Chinese hospitality major H World Group sells stake in OYO for Rs 75 cr

Godrej Group arm to invest Rs 100 cr to acquire material handling equipment

NMDC cuts iron ore lump rate by Rs 300 per tonne to Rs Rs 3,900 per tonne

First Published: May 30 2023 | 7:26 PM IST

Explore News